Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor worldwide and the third most common cause of cancer-related death [1] . Despite the availability of potentially curative therapies for localized HCC, most patients have unresectable tumors, either at presentation or upon recurrence. The treatment of patients with metastatic or locally advanced HCC presents a major challenge, because the associated cirrhosis limits the choice of chemotherapeutic agents. Further, the high chemoresistance of the tumour cells inhibits an effective systemic therapy for this neoplasia. In 2002 incidence of liver cancer in Central and Eastern Europe was 16,428 new cases per year (9674 for males and 6754 for females), with a mortality of 7.5% for males and 5% for females. The incidence in Southern Europe was 20,518 (14,021 for males and 6497 for females); Italy alone represented 58.3% of all cases in this region [2] . Those differences in the incidence could reflect differences in possibility of diagnosis, as well as difference in the risk factors endemic to different European regions.
Although many molecular changes have been identified in HCC, we are just beginning to identify the key molecular pathways involved in hepatocarcinogenesis and to assess the relevance of these as potential therapeutic targets [3] . Preclinical and clinical trials support the possibility that other target therapies might produce some results in the control and cure of this disease. Several important intracellular signalling pathways, such as the Ras/Raf/Mek/Erk pathway and the PI3k/Akt/mTOR pathway, have been recognized. Aberrant Vascular Endothelial Growth Factor (VEGF) expression has been demonstrated in HCC; several studies have suggested a relationship between HCC vascularity and VEGF expression [4] . Moreover, tumour expression of VEGF correlates with tumour invasiveness, and high pre-treatment serum VEGF levels predict poor prognosis after radiofrequency ablation [5] . The use of anti-vascular or cell cycle blockers agents might be a promising approach in view of the highly vascular and chemoresistant nature of this tumour.
Clinical trials indicate that growth factor receptors and their related signalling pathways play important roles in HCC cancer aetiology and progression, thus providing rational targets for innovative cancer therapies. After the publication of the results of the phase III clinical trial (SHARP trial), an interesting possibility for treatment this disease is now available with an increase in median survival and the time to radiologic progression [6] . Although sorafenib showed a statistically significant increase of survival in the category of patients stratified for ECOG performance status or extension of disease, the quality of life of these patients was lessened by severe side effects, such as palmar plantar erythrodysesthesia (hand-foot syndrome) and diarrhoea.
The angiogenic and proliferative pathways can be target by several agents: monoclonal antibodies as bevacizumab or cetuximab can target extracellular signals of growth; tyrosine kinase inhibitors as sorafenib, erlotinib and sunitinib target intracellular vascular and growing pathways. At present, 46 active trials involving these molecules are registered at ClinicalTrials.gov: 18 involve sorafenib; 13, bevacizumab; 7, erlotinib; 6, sunitinib; and 2, cetuximab. Strikingly, only 3 of these 46 trials are recruiting patients in southern Europe, and none in the central or eastern areas [7] .
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The future for the treatment of this neoplasia has arrived, but the potentiality of these drugs must be completely understood through thorough clinical testing. Combined regimens could be the next approach for hepatocellular carcinoma, but safety and efficacy must be confirmed by ongoing and future trials. Equal accessibility of all European countries to these trials is important to establish the EU as a promoter of an effective health service for all its citizens.
